Royalty Report: Drugs, Disease, Diagnostic – Collection: 245958


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Diagnostic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245958

License Grant
The Netherlands Licensor and the Belgium Licensee hereby agree to amend the original agreement to extend arrangements in the development and exploitation of galantamine for use in the treatment of Obstructive Sleep Apnoea and in Japan for Alzheimers disease and Chronic Fatigue Syndrome.
License Property
Licensed Product(s)  any product containing Galantamine (whether Natural Galantamine and/or Synthetic Galantamine) which is used for, and/or intended to be used for
(1) the treatment of Alzheimers disease and/or related dementia
(2)  the treatment of OSA (Obstructive Sleep Apnoea)
(3)  the treatment of CFS (Chronic Fatigue Syndrome)
(4)  other indications as referred to in the Agreement
Field of Use
This Agreement pertains to the drug industry.

IPSCIO Record ID: 213206

License Grant
The Irish Licensor grants the Licensee a worldwide license for the use of Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease.
License Property
Trelegy Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD), a group of diseases that includes chronic bronchitis and emphysema.

COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26783

License Grant
We acquired an interest in Chronix.
License Property
Chronix focuses upon the development of diagnostics for chronic diseases.  The collaborative research is an effort to develop intellectual property on potential new products for diagnosing and treating various chronic illnesses such as ME/CFS.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease that is difficult to diagnose and for which, at present, there is no cure.  People suffering from this illness experience, among other symptoms, a constant tiredness, recurring dull headaches, joint and muscle aches, a feeling of feverishness and chills low grade fever, depression, difficulty in concentrating on tasks, and tender lymph glands.
Field of Use
The field of use relates to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.